Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cipher Pharmaceuticals Inc
T.CPH
Alternate Symbol(s):
CPHRF
Healthcare
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology...
products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CPH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on Nov 21, 2024 6:55am
Buzz on the Bullboards: Bombardier, world woes, a smart fridge, and top shelf weed
A highlight of the week was Bombardier (TSX:BBD), which reported impressive growth in its Q3 2024 results.
read article.
(126)
•••
Daudau11
X
View Profile
View Bullboard History
Comment by
Daudau11
on Nov 12, 2024 5:01pm
RE:RE:Stifel
Tbh, I don't see any stocks I own doing well lately. The only things that are going up nowadays are, Tech/AI and Crypto. Thats like it. Seems like the the market believes
...more
(9)
•••
drewmumaw
X
View Profile
View Bullboard History
Comment by
drewmumaw
on Nov 12, 2024 4:05pm
RE:Stifel
I had some time to scan the MD&A today. Let me know if I'm missing anything major, but my key takeaways were: Natroba strongly boosted product revenue. It only has 22% of the US market
...more
(6075)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Nov 12, 2024 6:52am
Stifel
Cipher Pharmaceuticals Target Lowered by Stifel Nicolaus C$19.00 C$17.00
(113)
•••
mjh9413
X
View Profile
View Bullboard History
Post by
mjh9413
on Nov 08, 2024 1:28am
interesting change in costs of operations
eom
(6075)
•••
retiredcf
X
View Profile
View Bullboard History
Comment by
retiredcf
on Nov 05, 2024 2:08pm
RE:Raised Target
Can't see any reason why the SP has fallen almost 17% in the past 3 weeks other than profit taking or investor jitters. Hopefully the upcoming earnings will reverse the trend. GLTA
(6075)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Oct 25, 2024 8:41am
Raised Target
Cipher Pharmaceuticals Target Raised by Stifel Nicolaus C$17.00 C$19.00
(6075)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Oct 15, 2024 9:26am
Ink Research
The INK CIN Index leaders last week were Bird Construction (Sunny; BDT), up 23.4%, Cipher Pharmaceuticals (Sunny; CPH), up 13.6%, and CI Financial (Mostly Sunny; CIX), up 9.8%. The laggards were Aura
...more
(6075)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Oct 10, 2024 10:29am
Good Looking Hire
"I am delighted to announce the addition of Dr. Ghanei to Cipher's executive team. Hamed's expertise in business development, including extensive experience with licensing deals and other
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 08, 2024 7:05am
New Press Release - Cipher Pharmaceuticals Enhances Leadership Team with Appointment of New Chief Business Officer
MISSISSAUGA, ON, Oct. 8, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today the appointment of Hamed Ghanei as Chief Business Officer ("CBO").Craig Mull, Interim Chief Executive Officer, commented on the appointment: "I am delighted to...
read article.
(1918)
•••
Possibleidiot01
X
View Profile
View Bullboard History
Comment by
Possibleidiot01
on Oct 01, 2024 7:26pm
RE:Planet Microcap Presentation CPH
The Q+A isn't the best part of the presentation - seems like leading questiions were asked and you YES/NO answers until the last one which is about the milestone payments due to Moberg and if i
...more
(1918)
•••
Possibleidiot01
X
View Profile
View Bullboard History
Post by
Possibleidiot01
on Oct 01, 2024 12:13pm
Dean@PettyCash , Substack
https://pettycash.substack.com/p/cph-update
(126)
•••
Daudau11
X
View Profile
View Bullboard History
Post by
Daudau11
on Sep 26, 2024 5:38pm
Planet Microcap Presentation CPH
https://www.webcaster4.com/Player/Index?webcastId=51093&g=2ec8b265-0753-4352-b554-2277e4cbfaaf&uid=6209799&sid=
(126)
•••
Daudau11
X
View Profile
View Bullboard History
Comment by
Daudau11
on Sep 26, 2024 10:56am
RE:Stifel Raises Target
Haha raised target yesterday and it was flatish and today dropped below $14
(6075)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Sep 25, 2024 9:17am
Stifel Raises Target
Stifel’s Justin Keywood moves his Cipher Pharmaceuticals Inc. target to $17 from $16 with a “buy” rating. The average is $17.63. “We raise our target price ... to reflect increased confidence
...more
(9)
•••
drewmumaw
X
View Profile
View Bullboard History
Comment by
drewmumaw
on Sep 18, 2024 10:18am
RE:RE:RE:RE:RE:RE:RE:Hits after hits on Small Caps
I wasn't on the call, unfortunately, so that's why I was asking. There's an interview with the Moberg CEO on Redeye, but it's in Swedish. https://www.redeye.se/research/1039785/moberg
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Options Trading for Retiring: Key Strategies in Balancing Retirement Income
One Property, One Focus on Advancing this Gold Project in Ontario